Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DEXCOM INC Director's Dealing 2023

Jan 21, 2023

30198_dirs_2023-01-20_8b0a2a5c-5a0d-45aa-978e-d1d2a09b3e92.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2023-01-18

Reporting Person: SAYER KEVIN R (Director, President CEO and Chairman of)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-11-03 Common Stock G 10000 $0.0 Disposed 381532 Direct
2023-01-18 Common Stock A 90720 $0.0 Acquired 472252 Direct

Footnotes

F1: The transaction represents a gift by the Reporting Person of 10,000 shares to a charitable donor advised fund.

F2: Included in this number are 134,792 unvested restricted stock units, 65,004 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 35,852 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 33,936 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

F3: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2020 that vested on January 18, 2023, with the applicable performance achieved.